Andrew Akbashev/X
Nov 11, 2025, 01:48
Andrew Akbashev: Globally, Life in Academia is Getting Worse
Andrew Akbashev, Senior Staff Scientist at PaulScherrer Institute, posted on X:
“Pressure to publish jumps. And researchers have no time to do science. (New survey from Elsevier)
Survey of 3200 researchers:
- Only 45% of scientists have sufficient time for actual research.
- For 68%, the pressure to publish today is greater than 2-3 years ago.
- 29% of researchers are considering relocating to another country (for better funding, work‐life balance, or greater research freedom).
- 58% of researchers use AI tools in their work.
- Reported benefits from AI: saving time (58%), helping with literature summaries (61%), literature reviews (51%), data analysis (38%), drafting proposals (41%), and drafting papers (38%).
Globally, life in academia is getting worse.
For students and postdocs – it’s especially hard to decide on an academic career.
A few days ago, I gave a lecture on this topic.
“PhD: Dreams, Reality and Consequences”
Watch it here:
(I’ll appreciate if you ‘like’ this video – you will GREATLY help it reach more students.)”

Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis